---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-274291"
form_type: "8-K"
ticker: "ODTX"
cik: "0001882782"
company_name: "Odyssey Therapeutics, Inc."
filed_at: "2026-06-17T20:45:18+00:00"
generated_at: "2026-06-17T20:46:26.377206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data

## Summary
- Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.
- Net loss of $38.3M for Q1 2026, comparable to $38.4M in Q1 2025.
- R&D expenses $32.3M (down $6.5M YoY); G&A $7.4M (down $0.6M YoY).
- Phase 2a proof-of-concept for OD-001: 27% clinical remission, 61% clinical response in UC.
- Plan to launch Phase 2b monotherapy and Phase 2a combo trial with vedolizumab in H2 2026; data H2 2027.

## SEC filing metadata
- accession: 0001193125-26-274291
- form_type: 8-K
- ticker: ODTX
- cik: 0001882782
- company_name: Odyssey Therapeutics, Inc.
- filed_at: 2026-06-17T20:45:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/0001193125-26-274291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/odtx-20260617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-274291
- JSON: https://secwatch.observer/filing/0001193125-26-274291.json
- Plain text: https://secwatch.observer/filing/0001193125-26-274291.txt

## Key facts
- Earnings Releases
  Odyssey Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income $38.3 million.
  - Period: the three months ended March 31, 2026
  - Net income: $38.3 million
  - Result: reported results
  source text: Net loss was $38.3 million for the quarter ended March 31, 2026, compared to a net loss of $38.4 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/0001193125-26-274291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.